Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC
Neal Shore, MD, FACS provides an analysis of the ARAMIS, SPARTAN, and PROSPER trials, which demonstrate improved survival in high-risk non-metastatic castration-resistant prostate cancer through early intervention, highlighting the potential for preventing disease progression based on the data from these pivotal studies.
EP: 1.Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case
EP: 2.Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC
EP: 3.Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC
EP: 4.Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment
EP: 5.Addressing Unmet Needs and Final Perspectives on nmCRPC
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen
